Oncology Pharmacy Specialty Review Course (Cert # L199063)

ACPE Numbers: Various – see listing below
Release Date:  01/15/19
Expiration Date: 06/25/19
Activity Type: Application-based
CE Credits: 25.75 hours (ACPE only)
Activity Fee: $495 (ASHP member); $640 (non-member) 

Accreditation for Pharmacists

The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience

These activities are intended for pharmacists who are seeking to update their knowledge and skills commensurate with a board certification examination in the areas listed below. 

Activity Overview

This online course provides a robust preparatory curriculum for the pharmacy professional preparing for the Board of Pharmacy Specialties (BPS) Oncology Pharmacy Specialty Certification Examination. Designed based on the domains, tasks, and knowledge statements developed by the BPS for the certification examination, this course will help you prepare for the exam by identifying areas needed for in‐depth review of oncology issues.

This course is NOT intended for those obtaining recertification credit. 

Review Course

This course consists of 21 modules, which are broken into 5 sections (see table below) and provides up to 25.75 hours of continuing pharmacy education credit. Using a case-based approach, the course strongly emphasizes the thought processes needed to solve patient care problems in each therapeutic area.          

Learning Module

ACPE Number

Credit Hours

Blood Cancers and Hematopoietic Stem Cell Transplantation

0217-9999-18-134-H01-P

5.5

Solid Tumor Cancers and Cancer-related Infectious Diseases

0217-9999-18-135-H01-P

4.75

Women, Men, Pediatric Cancers

0217-9999-18-132-H01-P

5.75

GI and GU Cancers and Statistics/Evaluating Literature Design

0217-9999-18-133-H01-P

5

Practice Management, Multiple Myeloma, Adult Sarcoma, and Pharmacogenomics

0217-9999-18-136-H01-P

4.75


Learning Objectives                                               

At the end of the presentations, the pharmacist should be able to: 

Blood Cancers and Hematopoietic Stem Cell Transplantation
ACPE # 0217-9999-18-134-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adults with acute leukemia or myelodysplastic syndrome.
  • Assess the prognostic impact of relevant cancer‐related molecular biology testing for an adult with acute leukemia or myelodysplastic syndrome.
  • Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions from pharmacotherapy for acute leukemia and myelodysplastic syndrome in an adult, including tumor lysis syndrome, neurotoxicity, differentiation syndrome, and cardiac toxicity from arsenic trioxide, and other agents as appropriate.
  • Determine appropriate pharmacotherapy for acute leukemia or myelodysplastic syndrome in an adult based on genomic test results.
  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with chronic leukemia.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing in a patient with chronic leukemia.
  • Determine appropriate pharmacotherapy based on genomic test results in a patient with chronic leukemia.
  • Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for the treatment of cancers, including: Infusion-related reactions from monoclonal antibodies used in the treatment of hematologic malignancies, and Hematologic toxicities from tyrosine kinase inhibitors used to treat chronic myelogenous leukemia.
  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients undergoing hematopoietic stem cell transplantation (HSCT).
  • Debate the advantages and disadvantages of various methods of peripheral blood stem cell mobilization.
  • Discern dose‐limiting toxicities and appropriate strategies to prevent toxicity from chemotherapy agents employed in HSCT conditioning regimens, and differentiate between myeloablative, non‐myeloablative, and reduced-intensity HSCT conditioning regimens.
  • Create a plan for prevention and management of acute and chronic graft‐versus‐host disease (GVHD) using appropriate systemic and ancillary therapies.
  • Discuss short‐ and long‐term treatment goals, including post-therapy and survivorship, with the patient undergoing HSCT and his or her caregiver.
  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lymphoma.
  • Assess the prognostic impact of cancer-related molecular biology testing for a patient with lymphoma.
  • Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation. 

Solid Tumor Cancers and Cancer-related Infectious Diseases
ACPE # 0217-9999-18-135-H01-P

  • Design an appropriate patient‐specific management and monitoring plan to address potential infection‐related problems that may arise during or following cancer treatment based on the current guidelines for treating cancer-related infectious diseases.
  • Determine short‐ and long‐term treatment goals, including post-therapy, with a patient with a cancer-related infectious disease and his or her caregiver.
  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, or adult central nervous system (CNS) cancer.
  • Assess relevant pharmacogenomic considerations related to anticancer agents used to treat head, neck, or CNS cancer.
  • Select relevant information and provide guidance to the public regarding head and neck-related issues (e.g., risk factors, prevention, screening).
  • Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cachexia, mucositis, and xerostomia.
  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lung cancer.
  • Identify relevant cancer-related molecular biology testing for a patient with lung cancer.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lung cancer.
  • Select relevant information and guidance for the public regarding lung cancer-related issues (e.g., risk factors, prevention, screening).
  • Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lung cancer, including pulmonary toxicities from PD1 inhibitors.
  • Develop and communicate a prevention and management strategy for chemotherapy-induced nausea and vomiting for patients with any type of cancer.
  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with melanoma or non-melanoma skin cancer.
  • Identify relevant cancer-related molecular biology testing for a patient with melanoma skin cancer.
  • Determine long-term treatment goals, including post-therapy and survivorship, with a patient with melanoma or non-melanoma skin cancer and his or her caregiver.
  • Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g., risk factors, prevention, screening).
  • Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with the treatment of melanoma and non-melanoma skin cancers, including thyroid level monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAF inhibitors.
  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities and outcomes, based on the most current guidelines for patients with thyroid cancer.
  • Devise and communicate appropriate plans for preventing, monitoring and treating adverse reactions associated with the pharmacotherapy for thyroid cancers. 

Women, Men, Pediatric Cancers
ACPE # 0217-9999-18-132-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with breast cancer.
  • Discuss short‐ and long‐term treatment goals, including post‐therapy and survivorship, with a patient with breast cancer and her or his caregiver.
  • Determine appropriate pharmacotherapy for a patient with breast cancer based on genomic test results.
  • Identify appropriate diagnostic and prognostic tests related to breast cancer.
  • Select relevant information and guidance for the public regarding breast cancer‐related issues (e.g., risk factors, prevention, screening).
  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes of clinical trials and current treatment guidelines for a patient a with a gynecologic malignancy.
  • Discuss short- and long-term goals, including post-therapy and survivorship, with a patient with a gynecologic malignancy and her caregiver.
  • Compare and contrast the efficacy and toxicity of different routes of drug administration, including IP chemotherapy, in the treatment of ovarian cancer.
  • Select relevant information and provide guidance for the public regarding gynecologic malignancy‐related issues (e.g., risk factors, prevention and screening) for gynecologic malignancies.
  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for pediatric patients with cancer.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing for a pediatric patient with cancer.
  • Discuss with a pediatric patient who has cancer and his or her caregiver the short- and long-term treatment goals, including post-therapy and survivorship.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a pediatric patient with cancer.
  • Assess the regulatory, ethical, and patient rights issues related to conducting research, including informed consent and confidentiality.
  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with prostate cancer.
  • Identify appropriate diagnostic, prognostic, and monitoring tests for a patient with prostate cancer.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with prostate cancer and his caregiver.
  • Select relevant information and guidance for the public regarding prostate cancer-related issues (e.g., risk factors, prevention, screening). 

GI and GU Cancers and Statistics/Evaluating Literature Design
ACPE # 0217-9999-18-133-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal, or testicular cancer.
  • Determine short- and long-term treatment goals, including post-therapy and survivorship, with a patient with bladder, renal, or testicular cancer and his or her caregiver.
  • Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with the treatment with tyrosine kinase inhibitors and mTOR inhibitors.
  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lower gastrointestinal (GI) or pancreatic cancers.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with lower GI or pancreatic cancers and his or her caregiver.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lower GI or pancreatic cancers.
  • Select relevant information and guidance for the public regarding lower GI and pancreatic cancer-related issues (e.g., risk factors, prevention, screening).
  • Devise and communicate appropriate plans for preventing, monitoring and treating adverse reactions associated with pharmacotherapy for lower GI or pancreatic cancers including chemotherapy-induced diarrhea, hand-foot syndrome, hand foot skin reaction, neurotoxicity from oxaliplatin, management of hypersensitivity reactions to monoclonal antibodies used for solid tumors and dermatologic toxicities from epidermal growth factor receptor inhibitors.
  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with esophageal, gastric, or hepatic malignancies.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer agents used for gastrointestinal malignancies.
  • Devise and communicate appropriate plans for preventing, monitoring, and treating radiation recall and other complications of radiation therapy.
  • Evaluate the oncology literature, including study design, methodology, statistical analysis, and applicability of the results to clinical practice for the oncology patient population.
  • Identify potential sources of bias and evaluate the appropriateness of conclusions drawn based on outcomes in an oncology study report.
  • Select an appropriate statistical test (parametric or nonparametric) for use in evaluating the findings from an oncology study based on the type of data (i.e., nominal, ordinal, continuous).
  • Critique the validity and interpret the results of various types of oncology studies (e.g., meta‐analyses, noninferiority trials).
  • Interpret findings from the use of study endpoints (e.g., objective response, time to progression, adverse events, quality of life, overall survival) in oncology research.
  • Define, calculate, and interpret sensitivity, specificity, positive and negative predictive values, measures of effect, correlation, and regression for an oncology study. 

Practice Management, Multiple Myeloma, Adult Sarcoma, and Pharmacogenomics
ACPE # 0217-9999-18-136-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma.
  • Adjust treatment and monitoring plans as needed based on the pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate).
  • Devise and communicate appropriate plans for preventing, monitoring, and managing common problems associated with the treatment of adult patients with cancer including neurotoxicity from ifosfamide and hemorrhagic cystitis.
  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with multiple myeloma.
  • Evaluate oncology pharmacy services for compliance with established REMS regulations and standards.
  • Devise and communicate appropriate plans for preventing, monitoring and treating adverse reactions associated with the treatment of cancers, including bone metastases in multiple myeloma patients and thromboembolism, hypercalcemia of malignancy, and spinal cord compression all oncology patients.
  • Evaluate oncology pharmacy services for compliance with established regulations and standards.
  • Select quality-improvement activities that enhance the safety and effectiveness of the medication-use process in oncology patient care.
  • Examine the professional practice standards and guidelines for the safe handling and administration of hazardous drugs.
  • Consider the national accreditation and federal regulatory requirements for the care of cancer patients receiving chemotherapy or other hazardous drugs.
  • Consider medication reimbursement and patient assistance programs to optimize drug availability for oncology patients.
  • Evaluate the resources and develop methods for handling and disposal of hazardous drugs and related materials.
  • Evaluate policies and procedures related to conducting research involving investigational drugs, including drug management in patients with cancer.
  • Identify appropriate considerations for genetic interpretation in both the germline and somatic settings utilizing next generation sequencing techniques.
  • Translate the results from somatic genetic testing into therapy recommendations based on prognostic, predictive and patient characteristics.
  • Recognize the place in therapy for companion diagnostic testing related to therapy decisions. 

Additional Resources 

ASHP Guidelines on Preventing Medication Errors 

Faculty 

Jill S. Bates, Pharm.D., M.S., BCOP, CPP
Clinical Pharmacist Practitioner
University of North Carolina Medical Center
Associate Professor of Clinical Education
UNC Eshelman School of Pharmacy
Chapel Hill, North Carolina
 

Sara Butler, Pharm.D., BCPS, BCOP
Clinical Oncology Pharmacy Specialist
Clinical Oncology Pharmacy Supervisor
Barnes-Jewish Hospital
Saint Louis, Missouri
 

Courtney C. Cavalieri, Pharm.D., BCOP
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah
 

Karen M. Fancher, Pharm.D., BCOP
Assistant Professor of Pharmacy Practice
Duquesne University Mylan School of Pharmacy
Clinical Pharmacy Specialist
Passavant Hospital - University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
 

Christopher A. Fausel, Pharm.D., MHA, BCOP
Clinical Manager - Oncology Pharmacy
Indiana University Health
Chairman of the Board
Hoosier Cancer Research Network
Indianapolis, Indiana
 

Monique Giordana, Pharm.D., BCOP
Hematology/Oncology Clinical Pharmacy Specialist
Regions Hospital and Cancer Care Centers
Saint Paul, Minnesota
 

Laure Ice, Pharm.D., BCPS, BCOP
Clinical Pharmacy Specialist
Spectrum Health
Grand Rapids, Michigan
 

Michelle L. Kussin, Pharm.D., BCOP
Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan-Kettering Cancer Center
New York, New York

Andrea Landgraf Oholendt, Pharm.D., BCOP
Manager - Clinical Pharmacy Services
The University of Texas MD Anderson Cancer Center
Houston, Texas

Steven Ludlow, Pharm.D., BCOP, BCPS
Medical Oncology Clinical Pharmacy Specialist
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida 

Elyse A. MacDonald, Pharm.D., M.S., BCPS
Drug Information Specialist
University of Utah Health
Salt Lake City, Utah
 

Anthony J. Perissinotti, Pharm.D., BCOP
Clinical Pharmacist Specialist - Inpatient Hematology
Adjunct Clinical Assistant Professor
University of Michigan Health System
Ann Arbor, Michigan
 

Danielle Roman, Pharm.D., BCOP
Manager - Clinical Pharmacy Services
Allegheny Health Network Cancer Institute
Pittsburgh, Pennsylvania
 

Christine M. Walko, Pharm.D., FCCP, BCOP
Personalized Medicine Specialist
H. Lee Moffitt Cancer Center
DeBartolo Family Personalized Medicine Institute
Associate Professor - Department of Oncologic Sciences
USF Morsani College of Medicine
Tampa, Florida
 

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Anthony J. Perissinotti: Consultant, Amgen, Astellas, and Teva Pharmaceuticals; Speakers Bureau, Genentech and Jazz Pharmaceuticals.
  • Christine M. Walko: Honorarium, Bristol-Myers Squibb and Merck & Co.
  • All other planners, presenters, and reviewers of this session report no financial relationships relevant to this activity. 

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs, and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ASHP and ACCP. 

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.